What is the appropriate intravenous cefuroxime dosage, dosing frequency, and treatment duration for a 48 kg patient with ASOM?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cefuroxime IV Dosing for 48kg Patient with ASOM

For a 48kg patient with acute suppurative otitis media (ASOM), administer cefuroxime 150 mg/kg/day IV divided every 6-8 hours (approximately 1.8g IV every 6 hours or 2.4g IV every 8 hours), for 10 days. This provides 4 doses per day if given every 6 hours, or 3 doses per day if given every 8 hours.

Dosing Calculation and Rationale

The FDA-approved pediatric dosing for cefuroxime is 50-100 mg/kg/day in equally divided doses every 6-8 hours for most infections 1. For more severe infections, 150 mg/kg/day (not to exceed maximum adult dosage) is recommended in equally divided doses every 8 hours 1.

For your 48kg patient:

  • Standard dosing: 50-100 mg/kg/day = 2,400-4,800 mg/day
  • Severe infection dosing: 150 mg/kg/day = 7,200 mg/day (exceeds adult maximum)
  • Practical approach: Use 150 mg/kg/day capped at adult maximum of 4.5g/day

Specific Regimen Options:

Option 1 (Every 6 hours):

  • 1,800 mg (1.8g) IV every 6 hours = 7,200 mg/day total
  • This provides 4 doses daily

Option 2 (Every 8 hours):

  • 2,400 mg (2.4g) IV every 8 hours = 7,200 mg/day total
  • This provides 3 doses daily
  • This is the preferred option as it aligns with guideline recommendations for complicated intra-abdominal infections 2

Duration of Treatment

10 days is the recommended duration for mastoiditis/ASOM complications 3. The WHO guidelines specifically recommend cloxacillin/flucloxacillin 50 mg/kg QDS for 10 days for mastoiditis, with ceftriaxone as second-line 3. While cefuroxime is not the first-line agent listed, when used, the 10-day duration should be maintained.

Important Clinical Considerations

Cefuroxime Coverage for ASOM:

Cefuroxime provides coverage against the typical ASOM pathogens:

  • Streptococcus pneumoniae (including penicillin-resistant strains with MIC <4 μg/mL)
  • Haemophilus influenzae (including β-lactamase producers)
  • Moraxella catarrhalis

Monitoring Requirements:

  • Renal function: Cefuroxime is 89% renally excreted 1. If creatinine clearance drops below 20 mL/min, reduce frequency to every 12 hours 1
  • Clinical response: Expect improvement within 48-72 hours
  • Switch to oral: Consider switching to oral cefuroxime axetil (500mg BID) after clinical improvement if patient can tolerate oral intake 1

Common Pitfalls to Avoid:

  1. Underdosing in adolescents/larger children: At 48kg, this patient may be approaching adult size. Don't automatically use lower pediatric doses—calculate based on weight and cap at adult maximum
  2. Inadequate duration: ASOM/mastoiditis requires full 10-day course, not the shorter 5-7 day courses used for simple infections
  3. Missing renal adjustment: Always check renal function and adjust if impaired
  4. Premature oral switch: Ensure clinical stability (afebrile, improving symptoms) before transitioning to oral therapy

Alternative Consideration:

If this represents complicated mastoiditis with concern for intracranial extension, ceftriaxone 50-100 mg/kg/day (2.4-4.8g) IV once or twice daily may be preferred as it achieves better CNS penetration and is specifically recommended in multiple guidelines for mastoiditis 3, 4.

References

Guideline

improving antibiotic prescribing for children in the resource-poor setting.

British Journal of Clinical Pharmacology, 2015

Guideline

panel 7: otitis media: treatment and complications.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.